221 related articles for article (PubMed ID: 8289199)
1. 6,6-Disubstituted Hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors.
Soyka R; Heckel A; Nickl J; Eisert W; Müller TH; Weisenberger H
J Med Chem; 1994 Jan; 37(1):26-39. PubMed ID: 8289199
[TBL] [Abstract][Full Text] [Related]
2. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
Soyka R; Guth BD; Weisenberger HM; Luger P; Müller TH
J Med Chem; 1999 Apr; 42(7):1235-49. PubMed ID: 10197967
[TBL] [Abstract][Full Text] [Related]
3. On the bioisosteric potential of diazines: diazine analogues of the combined thromboxane A2 receptor antagonist and synthetase inhibitor Ridogrel.
Heinisch G; Holzer W; Kunz F; Langer T; Lukavsky P; Pechlaner C; Weissenberger H
J Med Chem; 1996 Sep; 39(20):4058-64. PubMed ID: 8831771
[TBL] [Abstract][Full Text] [Related]
4. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
Cozzi P; Giordani A; Menichincheri M; Pillan A; Pinciroli V; Rossi A; Tonani R; Volpi D; Tamburin M; Ferrario R
J Med Chem; 1994 Oct; 37(21):3588-604. PubMed ID: 7932586
[TBL] [Abstract][Full Text] [Related]
5. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193
[TBL] [Abstract][Full Text] [Related]
6. Labeling of human platelet plasma membrane thromboxane A2/prostaglandin H2 receptors using SQB, a novel biotinylated receptor probe.
Komiotis D; Wencel-Drake JD; Dieter JP; Lim CT; Le Breton GC
Biochem Pharmacol; 1996 Sep; 52(5):763-70. PubMed ID: 8765474
[TBL] [Abstract][Full Text] [Related]
7. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
[TBL] [Abstract][Full Text] [Related]
8. ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.
Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
Br J Pharmacol; 1993 Dec; 110(4):1600-6. PubMed ID: 8306107
[TBL] [Abstract][Full Text] [Related]
9. Thromboxane A2/prostaglandin endoperoxide (TXA2/PG-END) receptor binding properties in human platelets of ridogrel, a combined TXA2 synthase inhibitor--TXA2/PG-END receptor antagonist.
Heylen L; De Clerck F; Somers Y; Leysen JE
Blood Coagul Fibrinolysis; 1991 Oct; 2(5):617-21. PubMed ID: 1838285
[TBL] [Abstract][Full Text] [Related]
10. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
Weber C; Beetens JR; Tegtmeier F; Van Rooy P; Vercammen E; Wouters L; De Clerck F
Thromb Haemost; 1992 Aug; 68(2):214-20. PubMed ID: 1412169
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of potent, long-acting thromboxane receptor antagonists, SQ 33,261 and SQ 33,552.
Harris DN; Michel IM; Goldenberg HJ; Hartl KS; Allen GT; Steinbacher TE; Schumacher WA; Han WC; Hall SE; Floyd DM
J Pharmacol Exp Ther; 1992 Apr; 261(1):131-7. PubMed ID: 1532833
[TBL] [Abstract][Full Text] [Related]
12. 7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors.
Naka M; Mais DE; Morinelli TA; Hamanaka N; Oatis JE; Halushka PV
J Pharmacol Exp Ther; 1992 Aug; 262(2):632-7. PubMed ID: 1386885
[TBL] [Abstract][Full Text] [Related]
13. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
Hoet B; Arnout J; Deckmyn H; Vermylen J
Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
[TBL] [Abstract][Full Text] [Related]
15. Effects of terbogrel on platelet function and prostaglandin endoperoxide transfer.
Muck S; Weber AA; Schrör K
Eur J Pharmacol; 1998 Feb; 344(1):45-8. PubMed ID: 9570446
[TBL] [Abstract][Full Text] [Related]
16. Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives and related compounds.
Takeuchi K; Kohn TJ; True TA; Mais DE; Wikel JH; Utterback BG; Wyss VL; Jakubowski JA
J Med Chem; 1998 Dec; 41(27):5362-74. PubMed ID: 9876106
[TBL] [Abstract][Full Text] [Related]
17. Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function.
Dogné JM; de Leval X; Neven P; Rolin S; Wauters J; David JL; Delarge J; Massereel B
Prostaglandins Leukot Essent Fatty Acids; 2000 May; 62(5):311-7. PubMed ID: 10883063
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary pharmacology of DT-TX 30 SE, a potent selective combined thromboxane synthetase inhibitor and receptor antagonist, in guinea pigs.
Meade CJ; Muacevic G; Ward P; Soyka R
Jpn J Pharmacol; 1996 Jun; 71(2):119-27. PubMed ID: 8835638
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531.
Dogné JM; Rolin S; de Leval X; Benoit P; Neven P; Delarge J; Kolh P; Damas J; David JL; Masereel B
Cardiovasc Drug Rev; 2001; 19(2):87-96. PubMed ID: 11484064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]